Title |
Novel targets for Huntington’s disease: future prospects
|
---|---|
Published in |
Degenerative Neurological and Neuromuscular Disease, May 2016
|
DOI | 10.2147/dnnd.s83808 |
Pubmed ID | |
Authors |
Sarah L Mason, Roger A Barker |
Abstract |
Huntington's disease (HD) is an incurable, inherited, progressive, neurodegenerative disorder that is characterized by a triad of motor, cognitive, and psychiatric problems. Despite the noticeable increase in therapeutic trials in HD in the last 20 years, there have, to date, been very few significant advances. The main hope for new and emerging therapeutics for HD is to develop a neuroprotective compound capable of slowing down or even stopping the progression of the disease and ultimately prevent the subtle early signs from developing into manifest disease. Recently, there has been a noticeable shift away from symptomatic therapies in favor of more mechanistic-based interventions, a change driven by a better understanding of the pathogenesis of this disorder. In this review, we discuss the status of, and supporting evidence for, potential novel treatments of HD that are currently under development or have reached the level of early Phase I/II clinical trials. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 3% |
Unknown | 28 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 21% |
Student > Bachelor | 4 | 14% |
Researcher | 4 | 14% |
Student > Ph. D. Student | 3 | 10% |
Other | 2 | 7% |
Other | 2 | 7% |
Unknown | 8 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 4 | 14% |
Neuroscience | 3 | 10% |
Medicine and Dentistry | 3 | 10% |
Psychology | 3 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
Other | 3 | 10% |
Unknown | 11 | 38% |